Pathology Research International 5 Table 2: Clinical trials with retrospective subset analyses of antiEGFR eﬃcacy in relation to KRAS mutation status. Study Setting Treatment KRAS genotype No. of patients ORR (%) Single arm studies mPFS (mos) mOS (mos) Lie`vre et al. [34] De Roock et al. [29] Khambata-Ford et al. [28] Di Fiore et al. [47] Benvenuti et al. [48] Second-line treatment Irinotecan refractory Second or third-line treatment Refractory disease Various lines of treatment Cetuximab Cetuximab or cetuximab + irinotecan Cetuximab Cetuximab + chemotherapy Cetuximab or panitumumab or cetuximab + chemotherapy Amado et al. [24] Refractory disease Panitumumab + BSC vs. BSC Van Cutsem et al. [33] tFrierastt-mliennet Van Cutsem et al. [42] tFrierastt-mliennet Bokemeyer et al. [31] Bokemeyer et al. [43] First-line treatment First-line treatment FOLFIRI + cetuximab vs. FOLFIRI FOLFIRI + cetuximab vs. FOLFIRI FOLFOX + cetuximab vs. FOLFOX FOLFOX + cetuximab vs. FOLFOX Karapetis et al. [35] Refractory disease Cetuximab + BSC vs. BSC Siena et al. [44] Kohne et al. [45] First-line treatment First-line treatment FOLFOX + panitumumab vs. FOLFOX FOLFIRI + panitumumab WT = 656 Mut = 440 WT Mut Randomized studies WT Mut WT Mut WT Mut WT Mut WT Mut WT Mut vs. WT Mut WT Mut vs. WT Mut WT Mut vs. WT Mut WT Mut vs. WT Mut WT Mut vs. WT Mut WT Mut vs. WT Mut 65 24 57 46 50 30 43 16 32 16 124 84 119 100 172 105 176 87 316 214 350 183 61 52 73 47 82 77 97 59 115 81 113 83 85 57 40∗ 0 41† 0 10 0 20.3 0 31 6 17 0 0 0 59.3 36.2 43.2 40.2 57.3∗ 31.3 39.7 36.1 61∗ 33 37 49 57∗ 34 34 53 12.8 1.2 0 0 55 48 48 29 34 wk† (combo) 44.7 wk† (combo) 12 (cetux) 27 wk (cetux) 12 25.3–27.3 31.4 wk∗ 10.1 12.3 wk∗ 7.4 wk 7.3 wk 7.3 wk N.R. N.R. N.R. 9.9∗ 7.6 8.7 8.1 9.9∗ 7.4 8.4 7.7 7.7∗ 5.5 7.2 8.6 8.3∗ 5.5 7.2 8.6 3.7∗ 1.8 1.9 1.8 9.6 (wt)∗ 7.3 (mut) 8.0 (wt) 8.8 (mut) N.R. 14.3∗ 10.1 N.R. N.R. N.R. 8.1 4.9 7.6 4.4 24.9 17.5 21.0 17.7 23.5∗ 16.2 20.0 16.7 N.R. 22.8 18.5 13.4 17.5 9.5∗ 4.5 4.8 4.6 N.R. N.R.